Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy ; volume:14 ; number:1 ; day:18 ; month:4 ; year:2024 ; pages:1-9 ; date:12.2024
Scientific reports ; 14, Heft 1 (18.4.2024), 1-9, 12.2024
- Creator
-
Brun, Sinne Søberg
Hansen, Torben Frøstrup
Wen, Sara Witting Christensen
Nyhus, Christa Haugaard
Bertelsen, Lisbeth
Jakobsen, Anders
Hansen, Torben Schjødt
Nederby, Line
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41598-024-59791-0
- URN
-
urn:nbn:de:101:1-2406302124448.205565186604
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Brun, Sinne Søberg
- Hansen, Torben Frøstrup
- Wen, Sara Witting Christensen
- Nyhus, Christa Haugaard
- Bertelsen, Lisbeth
- Jakobsen, Anders
- Hansen, Torben Schjødt
- Nederby, Line
- SpringerLink (Online service)
Other Objects (12)
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab
Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis
Author Correction: Prognostic value of soluble programmed death-1 and soluble programmed death ligand-1 in severe traumatic brain injury patients
Metastatic Melanoma Treatment with Pembrolizumab after Hypersensitivity Reaction to Nivolumab: A Case Report
Fulminant Marginal Keratitis Induced by Atezolizumab, a Programmed Death Ligand 1 Inhibitor for Lung Cancer
Autoimmune Nebenwirkungen von Nivolumab, Ipilimumab und Pembrolizumab : Chancen und Risiken der Therapie mit Checkpoint-Inhibitoren
Pembrolizumab
Nivolumab plus ipilimumab versus nivolumab in individuals with treatment-naive programmed death-ligand 1 positive metastatic soft tissue sarcomas: a multicentre retrospective study